Ensysce Biosciences, Inc.(ENSC)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Ensysce Biosciences, Inc. (ENSC) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ENSC at 29.2/100 on a 32-signal composite quality model, placing it at rank #2,536 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Ensysce Biosciences, Inc. reports quarterly revenue of $1.2M, net income of $-2.6M. Top institutional holders of ENSC by reported 13-F value include JANE STREET GROUP, ADAGE CAPITAL PARTNERS GP, L.L.C., Virtu Financial, based on the most recent SEC filings. ENSC trades on the Nasdaq exchange and files with the SEC under CIK 1716947. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ENSC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Ensysce Biosciences, Inc. directly from SEC EDGAR.